Skip to main navigation Investors & Media Investors ↓ Investors Overview News & Events Stock Information Corporate Governance Financials & Filings IR Resources Corporate Profile Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapeutics that seek to halt progression of fibrotic diseases — ultimately preserving organ function. Our lead product candidate, PLN-74809, is an orally available small molecule designed to be a selective inhibitor of αvβ1 and αvβ6, two integrins that play key roles in multiple fibrotic pathways. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). We are currently conducting Phase 2a trials of PLN-74809 for the treatment of IPF and plan to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant’s second clinical stage product candidate, PLN-1474, is designed to be a small molecule selective inhibitor of αvβ1, targeting liver fibrosis associated with nonalcoholic steatohepatitis (NASH) and is partnered with Novartis. PLN-1474 is currently in Phase 1 testing. In addition to our clinical stage programs, we currently have preclinical programs targeting oncology and muscular dystrophies. Latest News Pliant Therapeutics to Participate in Upcoming Investor Conferences 11-18-2021 Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results 11-09-2021 Pliant Therapeutics to Participate in Piper Sandler Lung Day 10-07-2021 Pliant Therapeutics Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis 09-07-2021 Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis 09-03-2021 All Press Releases → Latest Presentation Pliant Therapeutics Corporate Presentation 11-09-2021 Latest Events Evercore ISI 4th Annual HealthconX Conference 11/30/2021 3:30 PM ET All Presentations → Stock Information PLRX (Common Stock) Exchange NASDAQ Price $15.02 Change (%) +0.71 (+4.96%) Volume 418,869 11/24/2021 4:00 PM EST Data Provided by Refinitiv. Minimum 15 minutes delayed. Investor and Media Contact: Christopher Keenan Vice President, Investor Relations and Corporate Communications ir@pliantrx.com About Our Science Pipeline Patients Investors & Media Careers Contact Terms of Use Privacy Notice CCPA Applicant and Staff Privacy Notice Copyright © 2021 Pliant Therapeutics, Inc. | All Rights Reserved